BASF's share price recently crossed above its 200-day moving average prompting investors to wonder if it is time to sell. Despite concerns, the company has been ramping up investment, particularly in the
biopharma and
pharmaceutical ingredients sectors in North America. While JPMorgan has cut BASF's stock rating and price target, the company announced a strategic partnership with
Equinor and signed a ten-year natural gas supply agreement. Adding complexity is Zacks Research's downgrade of the stock to a 'strong sell'. This suggests uncertainty in the market due to perceived weak financial prospects. Despite a steep drop in Q2 profits, the outlook remains steady and shares are rising. The company has also welcomed in new leadership with
Heather Remley now serving as president and CEO, additionally, the company has made significant investments in its
Cellasto line, funding a second plant in China while expansions have also been made in
alcoholates production. There have also been cuts to the company's 2025 outlook in response to tariffs affecting the global economy. Continued talks have been made regarding the potential listing of its agricultural chemicals division. As a whole, the company has been facing a mix of growth, setbacks, and adjustments necessitated by market dynamics.
BASF Stocks News Analytics from Wed, 07 Aug 2024 12:02:04 GMT to Sat, 23 Aug 2025 22:37:09 GMT -
Rating 1
- Innovation -5
- Information 5
- Rumor -4
